A novel small molecule aims to tackle both Alzheimer’s disease and Dravet syndrome
Maryam Mahdi |
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques.
Abnormal NMDA receptor activity is associated with a variety of neuro-psychiatric and neuro-degenerative diseases. Now, Genentech and Gladstone – an independent, non-profit biomedical research organization – are developing a new small molecule drug that increases the activity of NMDA receptors found at the synapses of brain cells as a potential therapy for Alzheimer’s disease and Dravet syndrome.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.